InfuSystems HoldingsINFU +0.77%88 EBITDA Margin % is 14.62% as of Mar. 2026, which is 13% below its 10-year median of 16.75. GuruFocus rates INFU with a GF Score™ of 88/100 and a GF Value™ of $9.44 (Fairly Valued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, InfuSystems Holdings ranks better than 73.04% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
InfuSystems Holdings EBITDA Margin % Related Terms
InfuSystems Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for InfuSystems Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INFU vs TANAF, INGN, LUCD: EBITDA Margin % Comparison
For the Medical Devices subindustry, InfuSystems Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InfuSystems Holdings EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where InfuSystems Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InfuSystems Holdings (INFU) has a EBITDA Margin % of 14.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InfuSystems Holdings and its competitors. This is 13% below median its historical median of 16.75. Over the past decade, InfuSystems Holdings' EBITDA Margin % has ranged from 12.10 to 23.44. According to the industry distribution chart, InfuSystems Holdings ranks #220 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 27%.
Is InfuSystems Holdings' EBITDA Margin % too high?
InfuSystems Holdings' current EBITDA Margin % of 14.62% is 13% below median its 10-year median of 16.75. Over the past 10 years, this metric has ranged from a low of 12.10 to a high of 23.44. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. InfuSystems Holdings' value of 14.62% is 95.6% above this industry median. Based on the distribution chart, InfuSystems Holdings ranks #220 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InfuSystems Holdings has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does InfuSystems Holdings' EBITDA Margin % compare to TANAF and INGN?
According to the Medical Devices & Instruments industry distribution chart, InfuSystems Holdings ranks #220 out of 816 companies for EBITDA Margin %. This puts InfuSystems Holdings in the upper half of its industry. The industry median EBITDA Margin % is 7.48. InfuSystems Holdings' value of 14.62% is 95.6% above this benchmark. Historically, InfuSystems Holdings' own EBITDA Margin % has ranged from 12.10 to 23.44 over the past decade. While the company's 10-year median is 16.75 vs. the industry median of 7.48, InfuSystems Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InfuSystems Holdings's current EBITDA Margin % of 14.62% is 95.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InfuSystems Holdings and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InfuSystems Holdings's current EBITDA Margin % is 14.62%, which is 13% below median its own 10-year median of 16.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InfuSystems Holdings stock overvalued right now?
Based on GuruFocus' analysis, InfuSystems Holdings (INFU) is currently considered Fairly Valued. The stock's GF Value™ is $9.44, compared to a current price of $9.15 — trading 3.1% below its estimated fair value. The current EBITDA Margin % is 14.62%, which is 13% below median its 10-year median of 16.75 and 95.6% above the Medical Devices & Instruments industry median of 7.48. InfuSystems Holdings' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For InfuSystems Holdings (INFU), the current EBITDA Margin % is 14.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InfuSystems Holdings (INFU) Overvalued in 2026?
Based on GuruFocus' analysis, InfuSystems Holdings stock appears to be undervalued.
The current stock price of $9.15 is trading 3.1% below its estimated GF Value™ of $9.44.
GuruFocus considers InfuSystems Holdings to be Fairly Valued.
Key valuation signals for INFU:
EBITDA Margin %: 14.62% (13% below median its 10-year median of 16.75)
GF Value™: $9.44 vs. price of $9.15 (3.1% below fair value)
Industry Position: 95.6% above the Medical Devices & Instruments median (#220 of 816)
No single metric tells the full story. See the INFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
88GF Score
Get the complete analysis for INFU
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INFU has been successfully added to your 
